Just days after gene editor Tome Biosciences announced undisclosed operational cuts, a clearer picture is coming into focus as 131 employees are being laid off. The biotech, which emerged with $ ...
For a full version of this story and related coverage, visit STAT. High-profile gene editing startup Tome Biosciences said in a legal filing Friday that it will terminate virtually its entire ...
Tome Biosciences, a gene editing startup that launched in late 2023 with $213 million in funding, will eliminate 131 positions in November, according to a Worker Adjustment and Retraining Act notice.
Tome Biosciences, a high-profile gene editing startup, will terminate nearly its entire workforce during the first two weeks of November.
Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
High-profile gene editing startup Tome Biosciences said in a legal filing Friday that it will terminate virtually its entire staff beginning Nov. 1. The Massachusetts WARN notice comes a day after ...
Despite the promise of its technology and funding from big backers, Tome Biosciences is “operating at reduced capacity” and weighing its “strategic options” as the Massachusetts-based company faces an ...
Buzzy gene-editing startup Tome Biosciences is floundering, just nine months after launching with $213 million in funding, according to several sources with direct knowledge of the matter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback